Because natural molecules have become promising therapeutic agents for treating osteoporosis by inhibiting RANKL‐induced osteoclastogenesis, it is necessary to study the mechanisms and value of these molecules for therapeutic use.30, 31 Unlike current treatments, which are challenged by side effects such as osteonecrosis and hormonal disorders,32 astilbin demonstrates good application value for the treatment of osteolytic diseases.12, 33. This evidence concerns the gene TNFSF11 and osteoporosis.